---
title: "Retatrutide: The Triple-Action GLP-1 That's Changing Weight Loss"
description: "A complete guide to retatrutide, the first triple agonist targeting GLP-1, GIP, and glucagon receptors. Clinical data, dosing, side effects, and how it stacks up against semaglutide and tirzepatide."
image: /images/articles/retatrutide.webp
published: 2026-02-14
category: weight-loss
tags: [retatrutide, GLP-1, GIP, glucagon, weight loss, obesity, triple agonist]
---

# Retatrutide: The Triple-Action GLP-1 That's Changing Weight Loss

If you've been following the weight loss peptide space, you already know about semaglutide and tirzepatide. They were big. But retatrutide might be bigger. It's the first triple agonist to hit clinical trials, targeting not two but three metabolic receptors at once. And the early data? Stunning.

Let's break down what retatrutide actually is, how it works, what the research shows, and where things stand right now.

## What Is Retatrutide?

Retatrutide (also known as LY3437943) is an investigational peptide developed by Eli Lilly. It belongs to a new class of drugs called triple hormone receptor agonists, or "triagonists." While semaglutide targets GLP-1 alone and tirzepatide hits both GLP-1 and GIP, retatrutide goes a step further. It activates three receptors simultaneously:

- **GLP-1** (glucagon-like peptide-1)
- **GIP** (glucose-dependent insulinotropic polypeptide)
- **Glucagon**

That third target is what makes retatrutide different from everything else in the pipeline. Glucagon receptor activation adds a metabolic dimension that the dual agonists simply don't have.

For a deeper look at the compound profile, check out the [retatrutide overview on PeptideArc](https://peptidearc.com).

## How Does Retatrutide Work?

To understand why three targets matter, you need to understand what each receptor does on its own.

### GLP-1 Receptor Activation

GLP-1 is the foundation. When you eat, your gut releases GLP-1, which tells your pancreas to produce insulin. But GLP-1 does more than manage blood sugar. It slows gastric emptying, meaning food sits in your stomach longer. You feel full faster and stay full longer. It also acts on the brain's appetite centers, reducing hunger at a neurological level.

This is the same mechanism behind Ozempic and Wegovy. It works. The question was always whether we could make it work better.

### GIP Receptor Activation

GIP is the second piece. Historically, researchers weren't sure whether GIP agonism would help or hurt weight loss. The data from tirzepatide settled that debate. GIP activation appears to enhance the effects of GLP-1, improving insulin sensitivity and potentially contributing to fat loss through mechanisms we're still working out.

There's some evidence that GIP signaling in the brain helps regulate energy balance and may reduce lipid accumulation in fat tissue ([Samms et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32866435/)).

### Glucagon Receptor Activation

Here's where retatrutide gets interesting. Glucagon is traditionally thought of as the "opposite of insulin." When blood sugar drops, glucagon tells the liver to release stored glucose. But glucagon does something else that matters for weight loss: it increases energy expenditure.

Glucagon receptor activation ramps up thermogenesis and fat oxidation. In plain terms, your body burns more calories and preferentially burns fat to do it. It also has direct effects on the liver, reducing fat accumulation there.

This is a big deal because fatty liver disease (NAFLD/MASLD) is epidemic among people with obesity, and none of the current GLP-1 drugs directly target hepatic fat metabolism the way glucagon does.

### The Triple Combo

Put all three together and you get a compound that:

1. Suppresses appetite (GLP-1 + GIP)
2. Improves blood sugar control (GLP-1 + GIP)
3. Slows digestion (GLP-1)
4. Increases calorie burn (glucagon)
5. Promotes fat oxidation (glucagon)
6. Reduces liver fat (glucagon)

The result is weight loss that attacks the problem from multiple angles at once. You're eating less, absorbing differently, and burning more. That's the theory, anyway. Let's look at what the actual trials found.

## Clinical Trial Results

### Phase 1 Data

Retatrutide's first-in-human study was published in 2022. It was a dose-ranging study in people with type 2 diabetes, and the results were promising enough to fast-track the compound into larger trials.

Participants receiving the highest doses lost significantly more weight than those on placebo over 12 weeks. But phase 1 trials are small. The real story came next.

### Phase 2 Data: The Big One

The phase 2 trial results were presented at the American Diabetes Association (ADA) 2023 Scientific Sessions and published in the *New England Journal of Medicine* ([Jastreboff et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37351564/)).

This was a 48-week, randomized, double-blind, placebo-controlled trial involving 338 adults with obesity (BMI of 30 or higher, or 27 with a weight-related comorbidity). Participants did not have diabetes.

The dosing groups and results:

- **1 mg:** about 8.7% body weight loss
- **4 mg (two escalation schedules):** about 17.1% to 17.5%
- **8 mg:** about 22.8%
- **12 mg:** about 24.2%
- **Placebo:** about 2.1%

Read that last number again. The 12 mg group lost an average of 24.2% of their body weight in 48 weeks. That's roughly 58 pounds for someone starting at 240. And the trial was only 48 weeks. The weight loss curves hadn't plateaued yet, suggesting even greater losses with longer treatment.

For context, semaglutide 2.4 mg (Wegovy) produced about 15-16% weight loss in the STEP trials, and tirzepatide topped out around 20-22% in SURMOUNT-1. Retatrutide's 24% blew past both.

### What About Diabetes?

A parallel phase 2 trial looked at retatrutide in people with type 2 diabetes ([Rosenstock et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37351563/)). In that population, the 12 mg dose produced about 16.9% weight loss at 36 weeks, with significant improvements in HbA1c (the long-term blood sugar marker). Many participants achieved HbA1c levels below 5.7%, which is technically in the non-diabetic range.

### Liver Fat Reduction

One of the most exciting secondary findings was the effect on liver fat. In a sub-study using MRI to measure hepatic fat content, participants on retatrutide 12 mg saw an 82% relative reduction in liver fat at 48 weeks. More than 80% of participants with fatty liver at baseline no longer met the threshold for MASLD by the end of the trial.

That's a remarkable finding. There are currently no approved drugs specifically for MASLD, and it's a condition affecting roughly a quarter of the global population.

## Dosing

Based on the phase 2 trials, retatrutide is administered as a once-weekly subcutaneous injection. The dosing follows a slow escalation protocol to minimize gastrointestinal side effects:

**Typical escalation (from the obesity trial):**

- Weeks 1-4: Starting dose (varies by target)
- Gradual increases every 4 weeks
- Target maintenance doses tested: 1 mg, 4 mg, 8 mg, or 12 mg weekly

The 12 mg dose showed the greatest efficacy but also the most side effects. The 8 mg dose offered a strong balance of efficacy and tolerability, with 22.8% weight loss and a somewhat better side effect profile.

It's worth emphasizing that these are clinical trial protocols. Retatrutide is not yet approved, so there are no official prescribing guidelines. The phase 3 trials will help determine the optimal dose for different populations.

## Side Effects

The side effect profile is similar to other GLP-1 receptor agonists, with gastrointestinal issues being the most common. Here's what the phase 2 data showed:

### Common Side Effects

- **Nausea:** The most frequent complaint, especially during dose escalation. Reported in about 25-45% of participants depending on dose.
- **Diarrhea:** Affected roughly 20-35% of participants at higher doses.
- **Vomiting:** Occurred in about 10-20% of participants.
- **Constipation:** Less common than with semaglutide, but still reported.
- **Decreased appetite:** Expected given the mechanism, and technically a therapeutic effect.

### Less Common Side Effects

- **Injection site reactions:** Mild redness or itching at the injection site.
- **Increased heart rate:** A small increase (2-4 bpm) was observed, consistent with other GLP-1 drugs.
- **Mild increases in serum lipase and amylase:** These are pancreatic enzymes. Elevations were generally not clinically significant, but pancreatitis risk needs monitoring.

### Discontinuation Rates

About 6-10% of participants in the higher-dose groups dropped out due to side effects, mostly GI-related. That's roughly comparable to tirzepatide and somewhat better than some semaglutide trials, though cross-trial comparisons are always imperfect.

### The Glucagon Question

One theoretical concern with glucagon receptor activation is blood sugar elevation, since glucagon's primary role is raising glucose. In practice, the GLP-1 and GIP components appear to counterbalance this effect. Blood sugar levels in the trials actually improved across all dose groups, even in non-diabetic participants. This was a key safety question, and the data has been reassuring so far.

## Retatrutide vs. Semaglutide vs. Tirzepatide

People want to know how these compounds compare. Here's a straightforward breakdown:

| | Semaglutide (Wegovy) | Tirzepatide (Zepbound) | Retatrutide |
|---|---|---|---|
| **Targets** | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| **Max weight loss (trials)** | ~16% | ~22% | ~24% |
| **Dosing** | Weekly injection | Weekly injection | Weekly injection |
| **FDA approved** | Yes | Yes | Not yet |
| **Liver fat reduction** | Modest | Moderate | Substantial |
| **GI side effects** | Common | Common | Common |

A few things to keep in mind. Semaglutide and tirzepatide have years of real-world data behind them. Retatrutide has phase 2 data with a few hundred participants. Phase 3 trials involve thousands and often reveal things phase 2 didn't catch.

Also, the weight loss numbers aren't directly comparable across trials. Different patient populations, different inclusion criteria, different study designs. But the general trend is clear: more targets seem to mean more weight loss, with retatrutide currently leading the pack.

For detailed comparisons of these compounds, [PeptideArc](https://peptidearc.com) maintains updated profiles on each.

## Mechanism Deep Dive: Why Glucagon Changes Everything

Let's talk more about why that third receptor matters so much.

With GLP-1 agonists alone, the primary driver of weight loss is reduced food intake. You eat less because you're less hungry and you feel full sooner. That's powerful, but it has limits. Your body adapts. Metabolic rate drops as you lose weight (a process called adaptive thermogenesis). Eventually, the reduced calorie intake and reduced metabolic rate reach equilibrium, and weight loss stalls.

Glucagon receptor activation disrupts this pattern. By increasing energy expenditure and fat oxidation, it works on the "calories out" side of the equation. Your body doesn't just take in less fuel. It burns more of what it has stored.

Research in animal models has consistently shown that glucagon agonism increases resting energy expenditure by 10-15% ([Habegger et al., 2010](https://pubmed.ncbi.nlm.nih.gov/20185758/)). If that translates to humans (and the weight loss data suggests it does), it means retatrutide users may experience less of the metabolic slowdown that plagues traditional dieting and even single-target GLP-1 therapy.

There's also the liver angle. Glucagon promotes hepatic fat oxidation and reduces de novo lipogenesis (the liver's creation of new fat). Given that fatty liver is both a consequence and a driver of metabolic dysfunction, cleaning up the liver may have cascading benefits for insulin sensitivity, inflammation, and cardiovascular risk.

## Current Availability and Legal Status

As of early 2026, retatrutide is **not approved** by the FDA or any other regulatory agency. It remains an investigational compound.

### Phase 3 Trials

Eli Lilly launched several phase 3 trials in 2023-2024:

- **TRIUMPH-1:** Evaluating retatrutide in adults with obesity without diabetes
- **TRIUMPH-2:** Looking at obesity with type 2 diabetes
- **TRIUMPH-3:** Focused on MASLD/fatty liver disease
- **TRIUMPH-4:** Cardiovascular outcomes

Results from these trials are expected to roll in through 2025-2026, with a potential FDA submission following positive results.

### Can You Get It Now?

Retatrutide is available through clinical trial enrollment at participating sites. Outside of that, some research chemical suppliers and compounding pharmacies in gray-market jurisdictions have offered "research" versions of the peptide. We can't recommend or endorse purchasing unapproved compounds from unregulated sources.

The risks of gray-market peptides include contamination, incorrect dosing, degradation, and legal consequences. If you're interested in retatrutide, the safest path is participation in a clinical trial or waiting for FDA approval.

### Expected Timeline

If phase 3 results are strong (and phase 2 suggests they will be), an FDA submission could come in late 2026 or 2027, with potential approval in 2027-2028. Eli Lilly has significant manufacturing infrastructure from tirzepatide, which could help with the rollout.

## Who Might Benefit Most From Retatrutide?

Based on the data so far, retatrutide could be particularly suited for:

- **People with significant obesity (BMI 35+)** who need more aggressive weight loss than current options provide
- **People with fatty liver disease** given the dramatic liver fat reductions in trials
- **People with type 2 diabetes and obesity** who want both weight loss and glucose control
- **People who've plateaued on semaglutide or tirzepatide** and need additional metabolic support

But again, this is speculative until phase 3 data confirms the phase 2 findings and the drug receives approval.

## Potential Concerns and Open Questions

No drug is perfect, and there are legitimate questions still to be answered:

**Long-term safety.** We have 48 weeks of data. What happens over 2, 5, or 10 years? Do the glucagon effects on the liver remain beneficial, or could chronic glucagon stimulation cause problems we haven't seen yet?

**Muscle mass.** GLP-1 drugs cause some lean mass loss alongside fat loss. Does the glucagon component make this better or worse? Some animal data suggests glucagon promotes protein catabolism, which could be a concern. The phase 3 trials include body composition measurements that should help answer this.

**Cancer risk.** All GLP-1 drugs carry a theoretical risk of thyroid C-cell tumors based on rodent studies. Retatrutide has the same precautionary labeling. Whether this translates to humans remains unclear after years of semaglutide use showing no signal.

**Rebound weight gain.** This is the elephant in the room for all obesity drugs. When people stop semaglutide, they regain most of the lost weight within a year ([Wilding et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35441470/)). Will retatrutide be any different? Probably not, which means it's likely a long-term or lifelong treatment.

**Cost and access.** Tirzepatide already costs over $1,000/month without insurance. Retatrutide will likely be priced similarly. Insurance coverage for obesity drugs remains inconsistent, creating significant access barriers.

## Frequently Asked Questions

### How much weight can you lose on retatrutide?

In the phase 2 trial, participants on the highest dose (12 mg weekly) lost an average of 24.2% of their body weight over 48 weeks. Individual results varied, with some participants losing over 30%. The 8 mg dose produced about 22.8% loss with fewer side effects.

### Is retatrutide better than Ozempic?

The phase 2 data suggests retatrutide produces significantly more weight loss than semaglutide (Ozempic/Wegovy). But "better" depends on your definition. Semaglutide has years of safety data, FDA approval, and proven cardiovascular benefits. Retatrutide is still experimental. Direct comparison requires more data.

### When will retatrutide be available?

Assuming positive phase 3 results, an FDA approval could come in the 2027-2028 timeframe. This is an estimate and could shift based on trial timelines and regulatory review.

### Is retatrutide safe?

Phase 2 data shows a side effect profile similar to other GLP-1 drugs, primarily gastrointestinal symptoms. No major safety signals have emerged, but longer-term data from phase 3 trials is needed. The glucagon component introduces unique considerations that are still being studied.

### Can you take retatrutide with other medications?

This hasn't been extensively studied. As with other GLP-1 drugs, the slowed gastric emptying could affect the absorption of oral medications. If retatrutide reaches the market, prescribers will need to consider drug interactions on a case-by-case basis.

### Will retatrutide be a pill or injection?

Current trials use a once-weekly subcutaneous injection. An oral formulation has not been announced, though Eli Lilly is working on oral versions of other peptide drugs.

### Does retatrutide cause muscle loss?

All significant weight loss, whether from drugs, surgery, or diet, involves some lean mass loss. The ratio of fat to lean mass loss with retatrutide hasn't been fully characterized. Resistance training and adequate protein intake are universally recommended to preserve muscle during any weight loss intervention.

### How is retatrutide different from tirzepatide?

The key difference is the glucagon receptor component. Tirzepatide targets GLP-1 and GIP. Retatrutide targets GLP-1, GIP, and glucagon. The glucagon activation increases energy expenditure and fat burning, potentially explaining the additional weight loss seen in trials. It also dramatically reduces liver fat, which tirzepatide does to a lesser extent.

## The Bottom Line

Retatrutide represents the next evolution in metabolic peptide therapy. The triple agonist approach, hitting appetite, insulin signaling, and energy expenditure all at once, has produced the most impressive weight loss data we've ever seen in a clinical trial. The liver fat data adds another compelling dimension.

But it's early. Phase 2 data with a few hundred participants is promising, not definitive. The phase 3 program will tell us whether these results hold up in larger, more diverse populations and over longer timeframes. Safety questions, especially around the glucagon component, need more time to answer.

If the phase 3 data confirms what phase 2 showed, retatrutide could become the most effective obesity treatment ever approved. That's a big "if," but it's one worth watching closely.

For ongoing updates on retatrutide and other metabolic peptides, visit [PeptideArc](https://peptidearc.com).
